Compare Logitech International SA (LOGI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Organon & Co. Common Stock — how do they compare? Logitech International SA trades at $101.12 (market cap $14.62B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Logitech International SA is far larger — about 4× Organon & Co. Common Stock's market cap, and Logitech International SA pays the higher dividend (1.61%). Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Organon & Co. Common Stock for 0 Days on average.
| LOGI | OGN | |
|---|---|---|
Market Cap | $14.62B | $3.62B |
Volume | 811,529 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $126.69 | $13.81 |
52-Week Low | $85.84 | $5.70 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $12.95B | $11.04B |
Dividend Yield | 1.61% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.16, up 2.88% today, with a bullish technical signal from moving averages and support at $101. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.85 beating expectations of $1.26. Fundamentals show robust profitability with a net margin of 16.28% and ROE of 35.29%, while recent news highlights new product launches and partnerships.
The outlook is positive with a consensus price target of $107, offering ~6% upside. Key opportunities include product innovation and market share gains, but risks involve chip shortages and competitive pressures. Analyst sentiment is mixed with 26% buy ratings, suggesting cautious optimism amid execution challenges.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
